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Diabetic patients have been increasing and this tendency has become a medical and social problem worldwide.1 There are 
some types of  diabetes, in which the prevalence of  type 2 diabetes 
mellitus (T2DM) has been higher without requiring insulin treat-
ment. On the other hand, type 1 diabetes mellitus (T1DM) has 
acute onset due to virus infection. Under such circumstances, there 
is a disease that has been clinically important in recent years. It is 
Latent autoimmune diabetes in adults (LADA). 
 As to LADA, there are both clinical and immunological 
characteristics between T2DM and T1DM. The genesis of  T1DM 
has been the autoimmune destruction of  islet β-cells in the pancre-
as. There are some major anti-islet autoantibodies, such as glutamic 
acid decarboxylase autoantibody (GADA), and T1DM shows a 
high prevalence of  GADA.2,3
 When positive GADA is observed in the patient with 
T2DM, the patient does not require insulin treatment during the 
early stage, but the patient may become insulin-dependent status 
within a few years. This subtype of  diabetes has been called LADA 
mainly in Europe and North American region.4 In contrast, in 
Japan and the Asian region, it has been called slowly progressive 
insulin-dependent (type 1) diabetes mellitus (SPIDDM),5 and/or 
LADA.6
 The characteristic point of  LADA would be a conceptual 
phenotype that exists between conventional T1DM and T2DM. 
Recently, there has been some clinical issues and challenges for 
LADA.7 They include the prevention of  progressive β-cell failure 
by dipeptidyl peptidase-4 (DPP-4) inhibitors, Glucagon-like pep-
tide-1 (GLP-1) analogs, metformin, and insulin.8 Furthermore, 
there was an investigation of  islet cells and exocrine pancreatic 
tissues in the pancreas for LADA which were positive for GADAs 
and islet cell antibody (ICA).9
 LADA is characterized for its rather less intensive auto-
immune situation and its broad clinical features.10 Patients with 
LADA are initially insulin independent at early stages and can 
be checked by examination of  islet-cell autoantibodies. Then, it 
is rather difficult to diagnose LADA in the usual clinical setting. 
Probably, there are lots of  cases of  LADA which would exist in the 
large group of  T2DM with higher misdiagnosis rate. 
 As a matter of  fact, the screening test for ICAs would be 
necessary for the patients with newly diagnosed as T2DM. Unless 
this exam of  antibodies is performed, a gradual decrease in the 
ability of  insulin secretion may be found later after years.10 Con-
sequently, LADA may show slower decreased pancreas function 
compared with that of  T1DM. Furthermore, patients with LADA 
can prepare the pathophysiological changes in advance a few years 
later, with the adequate therapeutic approach of  diabetic treat-
ment. 
 LADA has been characterized for the presence of  spe-
cific autoantibodies for the islet cells. It includes GADA and IA-2 
antibodies.11 This type is often diagnosed as T2DM at an early 
stage, but a few years later its diabetic status will develop to the 
degree similar to T1DM. This situation has been as rather popu-
lar in adulthood as in childhood.11 Thus, there is a possibility of  
misdiagnosis between T2DM and LADA just after the diagnosis 
of  diabetes. These patients are defined as LADA which has been 
one of  the subtypes of  autoimmune diabetes.12 Its specific points 
would be more heterogeneous than T1DM in a young person and 
slower changes to β-cell failure for years with necessary treatment 
of  insulin.13 
 From the guidelines of  the Immunology of  Diabetes So-
ciety (IDS), a patient with LADA has been defined by i) adult age 
of  onset usually more than 30-years, ii) insulin independence at 
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onset for at least 6-months, iii) positive results for islet-cell autoan-
tibodies.13 In contrast, there have much discussion and controversy 
concerning the definition of  LADA. It is rather difficult to show 
clear diagnostic guidelines at present. Consequently, the various 
situation of  LADA includes heterogeneous matters in phenotypic, 
immunological and genetic features. These phenomena probably 
come from the variability of  autoimmunity, insulin resistance and 
pancreatic β-cell impairment rate.14
 In clinical practice, LADA has been sometimes unnoticed 
among patients with T2DM. Its incidence may be supposed to be 
about 5-10% of  misdiagnosis rate.11 Actually, it is recommended to 
order the measurement of  the blood C-peptide value and autoanti-
body examination such as GADA in the patients with newly diag-
nosed as T2DM. It is necessary to make confirmation the diagno-
sis whether there is the possibility of  LADA or not.15 It is indeed 
that it cost some expense for the detecting GADA antibody, but it 
is crucial to be checked at the early stages of  diagnosis. Obtaining 
the data for GADA antibody, prevention for β-cells failure and 
other clinical diabetic disorder for the future can be prepared in 
advance.16 
 According to the study on GADA in 32 patients with 
LADA, 59% of  them showed positive results for the measurement 
of  GADA-ELISA method.17 Patients with positive ELISA had sig-
nificantly lower insulin secretion, suggesting the presence of  more 
cytotoxic GAD epitopes. Consequently, measuring the value of  
GADA may predict the ability of  insulin secretion in patients with 
LADA. 
 In the action LADA study, the majority of  subjects 
showed positive for GADA, while only 24.1% of  subjects were 
positive for at least two autoantibody types.18 There are some con-
troversies concerning the pathogenesis of  LADA, which has not 
been clarified yet. A recent study revealed a significant association 
between Islet cell antigen 512 (IA-2) positivity and increased body 
mass index (BMI).19 It may suggest two possibilities in obese or 
lean subjects for LADA. One is persisting low-grade inflammation 
with genetic susceptibility to T2DM in obese people, and another 
is specific immunological involvement with genetic susceptibility 
to T1DM in lean people.16
 Formerly, T1DM has been thought of  as a childhood 
disease. In the last decade, however, about 30% of  T1DM cases 
have been diagnosed after 30-years-old by statistical investiga-
tions.15 Thus, T1DM onset in adults becomes an important matter 
at present. From various studies, the incidence rate of  adult-onset 
autoimmune diabetes has been different in countries and ethnicity. 
It is rather higher in North Europe than American, Latino, and 
Asia.12,20 The prevalence of  LADA has been reported as follows: 
2.6% in the United Arab Emirates, 3.2% in India, 4.4%-5.3% in 
Korea, 5.7% in China, 7.0-14.0% in North Europe.20,21 In these 
studies, however, there have been various differences in study de-
sign, method, and criteria, where we have to compare the data of  
incidence and prevalence from a different area in the world.
 In summary, LADA has been recently found in various 
areas. When the patient is diagnosed as LADA, autoantibodies and 
the clinical course should be carefully monitored. The pathogen-
esis for LADA has been gradually elucidated and the development 
of  future research is expected.
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